骨髓增生异常综合征的造血干细胞移植治疗现状和进展  

Current status and development of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome

作　　者：刘蕊[1] 许兰平[1] 

机构地区：[1]北京大学人民医院,北京大学血液病研究所,北京市造血干细胞移植重点实验室,北京100044

出　　处：《临床血液学杂志》2017年第6期891-895,共5页Journal of Clinical Hematology

摘　　要：骨髓增生异常综合征（myelodysplastic syndrome,MDS）是一组源于造血干细胞的恶性克隆性疾病,异基因造血干细胞移植（allogeneic hematopoietic stem cell transplantation,allo-HSCT）是可能治愈MDS的唯一方法。随着对此疾病认识的不断深入、去甲基化药物（hypomethylating agents,HMAs）的应用以及造血干细胞移植技术的发展,Currently,the only potential curative therapy for myelodysplastic syndrome（MDS）is allogeneic hematopoietic stem cell transplantation（allo-HSCT）,whose status is not moved in spite of the widespread using of hypomethylating agents（HMAs）.Several prognostic scoring systems can be used for selecting candidates for alloHSCT.No conclusive evidence establishes that HMAs used as bridge treatment for modifying tumor burden prior to transplant can improve prognosis,thus an intended transplantation shouldn＇t be delayed for waiting for the effects of HMAs.Several retrospective studies have demonstrated the benefit of HMAs in prevention or treatment of relapse after allo-HSCT,though further evidence is needed.As haploidentical HSCT has a similar efficacy with matched HSCT in MDS treatment,the problem of lack of donor is settled in a degree.So this therapeutic method would attract more study interest and be applied more broadly.

关 键 词：骨髓增生异常综合征 造血干细胞移植 去甲基化药物 

分 类 号：R733.3[医药卫生—肿瘤]